Results 201 to 210 of about 58,068 (308)

Immigration enforcement in hospitals: a framework for health systems. [PDF]

Trauma Surg Acute Care Open
Sakran JV, McDonough K, Arciaga Z, Joseph B.   +3 more
europepmc   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Influence of Social and Demographic Factors on Retinoblastoma Outcomes in the United States: A Systematic Review. [PDF]

Cochrane Evid Synth Methods
Joshi V, Shaughnessy D, Dellavalle N, Leslie L, Edwards M, Luna-Fineman S, Waxweiler T, Li T, Qureshi R.   +8 more
europepmc   +1 more source

Delays and loss to follow-up in outpatient retinopathy of prematurity screening. [PDF]

J AAPOS
Daniel Y, DuPuis D, Jacobson A, Gappy C, Jakpor O.   +4 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Impact of Diagnosis-Intervention Packet (DIP) Payment Reform on County Hospitals: Evidence from Z City, China. [PDF]

J Healthc Leadersh
Peng X, Tan H, Chen Y.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Consideration for HPV vaccination recommendations in patients with vulvar dysplasia and malignancy following resection: A retrospective study investigating rural-urban vaccination practices in patients served by an academic medical center in the heartland. [PDF]

Gynecol Oncol Rep
Keese Z, Samson K, Ortiz Barragan S, McAlarnen LA.   +3 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Unpacking Multi-Layered Challenges in Palliative Care Transitions: A Descriptive Qualitative Study of Multidisciplinary Teams in China. [PDF]

J Multidiscip Healthc
Tang J, Li J, Wang X, Xiao M, Zhang Y, Tao H, Jiang Y, Yan Y, Zhao Q.   +8 more
europepmc   +1 more source